Replies to post #159060 on Biotech Values

[DewDiligence]

It isn't Gilenya's price that prevents usage…

Then why did you highlight the pricing comparison between Gilenya and Tecfidera in the first sentence of #msg-86271444?

You are correct that historically patients did not change MS drugs often. Sadly, that was yesterday.

I don’t understand your use of the word sadly in this context, nor do I agree that the “stickiness” of the MS market is a thing of the past.